Clinical trials
Liposarcoma clinical trials
Below are recruiting liposarcoma clinical trials, each written for real people, not researchers. We’re tracking 30 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06843967RecruitingPhase 1/Phase 2
Mirdametinib and palbociclib for liposarcoma
This trial tests two targeted drugs – mirdametinib and palbociclib – taken as pills for people with a specific aggressive type of liposarcoma (dedifferentiated liposarcoma) that has spread or can't be removed. The goal is to see if this combination can shrink or slow the tumor.
Basking Ridge, New JerseyAges 18 years+ - NCT06239272RecruitingPhase 1/Phase 2
Personalized treatment for NRSTS in children and young adults
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
Atlanta, GeorgiaAges Up to 30 years - NCT07261657RecruitingEarly Phase 1
N-803 for progressive sarcoma after T-cell therapy
This trial tests a drug called N-803 for people with synovial sarcoma or myxoid/round cell liposarcoma that has gotten worse after T-cell therapy. N-803 may help the immune system fight the cancer, and the study will see if it can slow or stop the cancer from growing.
Chicago, IllinoisAges 18–80 - NCT06025747RecruitingPhase 1
Abemaciclib plus radiation for liposarcoma before surgery
This trial tests a combination of the targeted drug abemaciclib and radiation therapy before surgery for people with a specific type of liposarcoma. The goal is to see if this combination can shrink the tumor and help make surgery more effective.
Seattle, WashingtonAges 18 years+ - NCT02275286RecruitingPhase 1/Phase 2
Trabectedin plus radiation for select soft tissue sarcomas
This trial studies whether adding a chemotherapy medicine called trabectedin to targeted radiation can help control certain soft tissue sarcomas. It focuses on specific cancer types and locations, aiming to shrink tumors while keeping radiation safe for nearby healthy organs.
BordeauxAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Phoenix, ArizonaAges 18 years+ - NCT07377747Recruiting
Study of treatment for recurrent retroperitoneal liposarcoma
This study looks at how well standard treatments work for people whose liposarcoma has come back in the same area. It helps doctors understand best ways to manage this rare cancer.
Atlanta, GeorgiaAges 18 years+ - NCT04224064Recruiting
Blood test to help diagnose and predict liposarcoma
This study looks for a new blood test marker that may help doctors diagnose liposarcoma and estimate how it may behave over time. You may be asked for a blood sample and consent, and the study may follow you to see how well the test works.
MontpellierAges 18 years+ - NCT04785196RecruitingPhase 1/Phase 2
Testing an MDM2 drug plus an immune therapy for advanced tumors
This trial tests APG-115 together with a PD-1 immune therapy in people with advanced liposarcoma or other advanced solid tumors. It may help by blocking tumor growth through a mix of direct tumor targeting and immune system activation.
Guangzhou, GuangdongAges 18 years+ - NCT05711615RecruitingPhase 1
Low-dose doxorubicin plus peposertib for advanced sarcoma
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT06389799RecruitingPhase 2
Pemigatinib and Retifanlimab for Advanced Liposarcoma
This trial tests two experimental drugs (pemigatinib and retifanlimab) for advanced dedifferentiated liposarcoma that has not responded to other treatments. It aims to see if this combination can shrink tumors or slow cancer growth.
OsloAges 18–100 - NCT06498648RecruitingPhase 1/Phase 2
Abemaciclib with gemcitabine for soft tissue sarcoma
This trial tests whether adding the targeted drug abemaciclib to standard chemotherapy (gemcitabine) works better against certain soft tissue sarcomas. It is for people whose tumors have a normal Rb gene, which may help the drug work.
Houston, TexasAges 18 years+ - NCT06957431RecruitingPhase 1
Zanzalintinib and eribulin for advanced leiomyosarcoma and liposarcoma
This trial tests a combination of two drugs, zanzalintinib and eribulin, for people with advanced leiomyosarcoma or liposarcoma that has progressed after prior treatment. The goal is to see if this combination can help shrink or slow the growth of these sarcomas.
St Louis, MissouriAges 18 years+ - NCT07173972RecruitingPhase 2
Proton radiation for inoperable soft tissue sarcoma
This trial studies a high-dose, shortened course of proton beam radiation for people with soft tissue sarcoma that cannot be removed by surgery. It aims to improve tumor control while reducing side effects.
BergenAges 18 years+ - NCT07432932Recruiting
Personalized treatment before surgery for high-risk sarcoma
This trial tests a precision medicine approach by giving targeted therapy before surgery for high-risk soft tissue sarcoma. The goal is to see if matching treatment to your tumor's type can improve outcomes.
LondonAges 18 years+ - NCT06975293RecruitingPhase 1/Phase 2
STC-15 with toripalimab for advanced cancers and sarcomas
This trial tests a new drug called STC-15, either alone or with another drug (toripalimab), for people with certain advanced cancers or sarcomas that have progressed after prior treatment. The goal is to see if this combination or single drug can help shrink tumors or slow the disease.
San Francisco, CaliforniaAges 18 years+ - NCT04715191RecruitingPhase 1
CAR T therapy for GPC3-positive pediatric solid tumors
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
Houston, TexasAges 1–21 - NCT04031677RecruitingPhase 3
Surgery with or without chemotherapy for high-risk retroperitoneal sarcoma
This trial studies whether adding chemotherapy before surgery helps people with high-risk retroperitoneal (abdominal-area) leiomyosarcoma or liposarcoma. The goal is to improve outcomes while comparing surgery alone versus surgery plus neoadjuvant chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT04699292Recruiting
Registry study for local treatment in soft tissue sarcoma
This registry collects coded information about adults with a specific soft tissue sarcoma (MLS) to better understand how local treatments help. If you qualify, you don’t necessarily receive a new drug in this study—your data is used to improve future care.
AmsterdamAges 18 years+ - NCT05607095RecruitingPhase 1
TIL therapy for advanced uveal melanoma and sarcomas
This trial tests using your own immune cells (TILs) to fight advanced uveal melanoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, or angiosarcoma. It aims to see if this treatment can shrink tumors or slow their growth.
Harrison, New YorkAges 18 years+ - NCT05492682RecruitingPhase 1
First-in-human treatment for cancer using a drug injected into tumors
This Phase 1 trial tests PeptiCRAd-1, a treatment injected into a tumor, to see how safe it is and whether it can shrink cancers. It studies people whose cancer has come back or can’t be treated with standard options.
FrankfurtAges 18 years+ - NCT06083883RecruitingPhase 1
NK cell therapy targeting NY-ESO-1 for sarcomas
This trial tests a new kind of immune therapy using your own natural killer (NK) cells that are specially trained to find and attack cancer cells that have the NY-ESO-1 target. It is for people with certain sarcomas or other advanced solid tumors that have not responded to prior treatments.
Houston, TexasAges 16–80 - NCT06198296RecruitingPhase 1
Armored CAR T cells for GPC3-positive solid tumors
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
Houston, TexasAges Up to 21 years - NCT06277154RecruitingPhase 2
MASCT-I plus chemo for first-line advanced soft tissue sarcoma
This trial tests a new immune cell therapy (MASCT-I) combined with standard chemotherapy (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior chemotherapy or targeted therapy. The goal is to see if the combination works better than chemo alone.
GuangzhouAges 18–70
Hear when a new Liposarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Liposarcoma trials by city
Studies with a site in or near these metro areas.
Liposarcoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for liposarcoma?
- Yes. Clin2 currently lists 30 recruiting liposarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liposarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liposarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.